

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Calabresi *et al.*

SERIAL NUMBER: 09/802,094

FILING DATE: March 8, 2001

FOR: Combination Drug Therapy

EXAMINER: C. Yaen

ART UNIT: 1614

May 13, 2002
Boston, Massachusetts



Commissioner for Patents
Washington, D.C. 20231

RECEIVED

MAY 20 2002

TECH CENTER 1600/2900

12
KB
5-28-02

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement (Paper 10) mailed on March 27, 2002, Applicants elect the invention of Group II, (claims 9-20), drawn to a method of tumor cell inhibiting tumor growth by administering a composition containing an inhibitor of angiogenesis and an inhibitor of DNA topoisomerase I. This election is made without traverse.

Applicant reserves the right to prosecute claims which are equal to or broader in scope in this, or future applications related to the above-identified patent application.

Applicants have filed concurrently herewith a petition for a one-month extension of time, along with a check to cover the \$55.00 extension fee pursuant to C.F.R. § 1.17 (a)(2). With the extension, the response is due on or before May 27, 2002. Although Applicant believes no further fees are due in connection with this filing, the Commissioner is hereby authorized to charge any fee that may be due to Deposit Account No. 50-0311 (Reference No. 21486-038).

Respectfully submitted,

IA Beattie
Ingrid A. Beattie, Reg. No. 42,306
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY & POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241